title: Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.
abstract: The relationship between osteonecrosis of the jaw and bisphosphonate therapy was initially established more than 10 years ago. Since that time our understanding of this disease process has evolved as the direct result of clinical, basic science, and animal research initiatives. Medication-related osteonecrosis of the jaw (MRONJ) is a well-known entity now known to be associated with various antiresorptive therapies and recently with antiangiogenic medications. This article reviews the recently modified diagnostic criteria for MRONJ with a focus on the clinical, histopathologic, and imaging characteristics of this disease process.
authors: Department of Oral and Maxillofacial Surgery, School of Dental Medicine, SUNY, Stony Brook, NY 11794-8705, USA; Hofstra North Shore - LIJ School of Medicine, Division of Oral and Maxillofacial Surgery, 270-05 76th Ave, New Hyde park, New York, NY 11040, USA. Electronic address: drruggiero@nycoms.com.
authors: Salvatore L
authors: SL
authors: Ruggiero
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000175:diagnosis; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D003952:Diagnostic Imaging; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D009626:Terminology as Topic
chemical_list: D020533:Angiogenesis Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates
keywords: Antiangiogenic therapy; Antiresorptive therapy; Jaw necrosis; Medication-related osteonecrosis of the jaw; Osteonecrosis